Biprogy Inc.
Biprogy Inc. (8056.T) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Biprogy Inc. (8056.T), covering cash flow, earnings, and balance sheets.
Biprogy Inc. (8056.T) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Biprogy Inc. 8056.T financial performance.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $124.75B | $93.23B | $97.68B | $88.35B |
| Cost of Revenue | $91.57B | $69.28B | $70.62B | $66.72B |
| Gross Profit | $33.17B | $23.96B | $27.06B | $21.64B |
| Gross Profit Ratio | $0.27 | $0.26 | $0.28 | $0.24 |
| R&D Expenses | $0.00 | $0.00 | $1.18B | $1.02B |
| SG&A Expenses | $19.04B | $16.96B | $14.92B | $15.31B |
| Operating Expenses | $19.04B | $16.74B | $16.09B | $15.06B |
| Total Costs & Expenses | $110.61B | $86.01B | $86.71B | $84.04B |
| Interest Income | $0.00 | $386.00M | $0.00 | $600.00M |
| Interest Expense | $551.00M | $0.00 | $917.00M | $48.00M |
| Depreciation & Amortization | $4.36B | $4.52B | $4.45B | $4.62B |
| EBITDA | $18.02B | $11.60B | $15.57B | $13.28B |
| EBITDA Ratio | $0.14 | $0.12 | $0.16 | $0.15 |
| Operating Income | $14.13B | $7.22B | $10.97B | $6.36B |
| Operating Income Ratio | $0.11 | $0.08 | $0.11 | $0.07 |
| Other Income/Expenses (Net) | -$1.16B | $984.00M | -$1.10B | $764.00M |
| Income Before Tax | $12.97B | $8.21B | $9.86B | $7.13B |
| Income Before Tax Ratio | $0.10 | $0.09 | $0.10 | $0.08 |
| Income Tax Expense | $3.47B | $2.63B | $3.18B | $2.25B |
| Net Income | $9.51B | $5.69B | $6.88B | $4.89B |
| Net Income Ratio | $0.08 | $0.06 | $0.07 | $0.06 |
| EPS | $96.79 | $57.72 | $69.60 | $48.65 |
| Diluted EPS | $96.59 | $57.72 | $69.60 | $48.54 |
| Weighted Avg Shares Outstanding | $98.45M | $98.53M | $98.81M | $100.78M |
| Weighted Avg Shares Outstanding (Diluted) | $98.45M | $98.53M | $98.81M | $100.78M |
Over the last four quarters, Biprogy Inc.'s revenue moved from $88.35B in Q1 2024 to $124.75B in Q4 2024. Operating income in Q4 2024 was $14.13B, with a strong operating margin of 11%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Biprogy Inc. remained robust at $18.02B, reflecting operational efficiency. Net income rose to $9.51B, with an EPS of $96.79. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan